Scientific article
English

Pharmacogenomics of Oral Antithrombotic Drugs

Published in

Current pharmaceutical design, vol. 22, no. 13, p. 1933-1949

Publication date

2016

Abstract

Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs' pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.

Citation (ISO format)

STORELLI, Flavia et al. Pharmacogenomics of Oral Antithrombotic Drugs. In: Current pharmaceutical design, 2016, vol. 22, n° 13, p. 1933–1949. doi: 10.2174/1381612822666151208122845

Identifiers

Journal ISSN

1381-6128
640views
0downloads

Technical informations

Creation

11/12/2015 15:16:00

First validation

11/12/2015 15:16:00

Update

13/10/2025 21:08:07

Status update

03/02/2025 11:30:01

Last indexation

28/09/2026 12:17:21
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated